Welcome to our dedicated page for Avid Bioservices news (Ticker: CDMOP), a resource for investors and traders seeking the latest updates and insights on Avid Bioservices stock.
Overview of Avid Bioservices
Avid Bioservices (CDMO) is a dedicated contract development and manufacturing organization specializing in the development and CGMP manufacturing of biologics. With over three decades of experience, the company offers a comprehensive suite of services that include process development, clinical and commercial drug substance manufacturing, and a broad range of testing and regulatory compliance services. Key industry terms such as CGMP manufacturing, process development, and biologics production are central to its operations, positioning Avid as an essential partner for biotechnology and pharmaceutical companies.
Core Business Areas
Avid Bioservices provides extensive services tailored to meet the evolving needs of life sciences companies. Its operations are divided into several critical segments:
- Process Development: Encompassing cell line development, upstream and downstream process optimization, analytical methods development, and comprehensive testing and characterization, this segment focuses on building a robust foundation for biologic production.
- CGMP Manufacturing: Operating state-of-the-art, fully compliant facilities, the company handles both clinical and commercial-scale production of drug substances. It covers bulk packaging, release and stability testing, and supports regulatory submissions.
- Comprehensive Support Services: In addition to production, Avid offers support in regulatory strategy, assay development, and data analysis, allowing clients to navigate the complex landscape of biologic development with confidence.
Market Position and Industry Significance
Avid Bioservices has established itself as a reliable partner in the highly specialized field of biologics development. Its longstanding track record of consistent regulatory compliance and commitment to quality has earned it trust among leading pharmaceutical and biotech innovators. The company’s ability to manage end-to-end services — from early-stage development to final commercialization — highlights its expertise and deep industry knowledge, making it a significant player in the global CDMO landscape.
Expertise and Operational Excellence
The company prioritizes technological innovation and process optimization to meet the rigorous demands of its clients. Its investments in state-of-the-art facilities and a skilled team proficient in analytical testing and regulatory affairs underline its commitment to operational excellence. Avid Bioservices continuously adapts its service offerings to address the evolving challenges in biologics manufacturing, ensuring high-quality and efficient treatment production.
Competitive Landscape
Avid competes in a dynamic and challenging marketplace alongside other renowned CDMOs. What sets it apart is its specialized focus on biologics, its comprehensive suite of services, and its dedication to maintaining robust regulatory standards. These factors enable the company to offer customized solutions that are not only technically advanced but also meticulously aligned with industry best practices.
Customer Focus and Value Proposition
The core value proposition of Avid Bioservices lies in its ability to support the sustainable innovation of biopharmaceutical products. By integrating advanced process development with scalable manufacturing solutions, the company helps clients bring complex biologics to market efficiently. Its customer-centric approach, underscored by tailored solutions and a deep understanding of regulatory frameworks, enhances overall client value across the product lifecycle.
Conclusion
With a rich history in biologics production, Avid Bioservices stands out for its unwavering commitment to quality, comprehensive service offerings, and precise, regulatory-compliant manufacturing practices. The company remains a crucial partner for biotechnology and pharmaceutical innovators looking for dependable, full lifecycle development and manufacturing solutions, underpinned by a deep well of industry expertise and operational excellence.
Avid Bioservices, Inc. (NASDAQ:CDMO) announced its participation in two investor conferences taking place in September 2021. The company will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, followed by 1-on-1 meetings from September 9-10 and 13-15. Avid will also present at the HC Wainwright 23rd Annual Global Investment Conference on September 13, with a corporate presentation available online at 7:00 a.m. Eastern. Both events feature virtual formats.
Avid Bioservices, Inc. (NASDAQ:CDMO) will release its first quarter fiscal year 2022 financial results on September 8, 2021, after market close. A conference call and webcast will take place at 1:30 PM PT for management to discuss these results and recent developments. The event aims to provide insights into the company's performance and ongoing initiatives. Investors can access the live audio through the company’s investor relations page.
Avid Bioservices (NASDAQ:CDMO) announced the appointment of Dr. Esther M. Alegria as an independent board member. Dr. Alegria brings nearly 30 years of biopharmaceutical experience, including her role as Senior VP of Global Manufacturing at Biogen. Her expertise spans R&D, manufacturing, and regulatory submissions, which is expected to support Avid’s growth strategy. Dr. Alegria currently leads APIE Therapeutics, focusing on novel treatments. The board expresses enthusiasm about her contributions to Avid's leadership and strategic direction.
Avid Bioservices recorded fourth quarter revenue of $27.6 million and annual revenue of $95.9 million, reflecting a 61% increase from the previous year. The company achieved four consecutive quarters of operational profitability and signed approximately $148 million in new business orders, resulting in a year-end backlog of $118 million. For fiscal 2022, revenue guidance is projected at $115 to $117 million, representing 20%-22% growth. Avid raised $138.5 million in a successful offering of convertible senior notes to support expansion efforts.
Avid Bioservices, Inc. (NASDAQ:CDMO) will report its financial results for the quarter and fiscal year ending April 30, 2021, on June 29, 2021, after market close. A conference call will be held at 1:30 PM PT (4:30 PM ET) to discuss these results and recent corporate developments. Avid is a contract development and manufacturing organization that specializes in biopharmaceutical drug manufacturing and offers a range of services including process development and regulatory support. Following 28 years of experience in the industry, Avid aims to enhance patient outcomes through quality services.
Avid Bioservices has been selected as the commercial manufacturer for ZYNLONTA™, a newly approved CD19-targeted antibody drug conjugate for adults with relapsed or refractory large B-cell lymphoma (DLBCL). This follows the FDA's approval of ZYNLONTA in April 2021. Avid has had a partnership with ADC Therapeutics since 2017 for clinical manufacturing and is expanding this relationship for commercial manufacturing. The expansion demonstrates Avid's experience and quality in supporting innovative biologic therapies.
Avid Bioservices announced the successful redemption of all outstanding 10.50% Series E Convertible Preferred Stock as of April 12, 2021. The company utilized proceeds from a recent offering of exchangeable senior notes to complete this redemption, with each share redeemed at $25.00 plus any accrued dividends. Consequently, the Series E Preferred Stock is no longer listed on NASDAQ as CDMOP. Avid Bioservices specializes in biologics contract development and manufacturing, focusing on high-quality services for the biopharmaceutical industry.
Avid Bioservices (NASDAQ:CDMO, CDMOP) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, taking place on March 23-24, 2021. CEO Nick Green will feature in a fireside chat on March 24 at 4:15 PM Eastern. The forum will be held virtually, providing a platform for Avid to showcase its commitment to high-quality biologics contract development and manufacturing services. Avid specializes in CGMP manufacturing for biopharmaceuticals, leveraging 28 years of experience in the industry.
Avid Bioservices, Inc. (CDMO, CDMOP) announced a private placement of $125 million in exchangeable senior notes due 2026, scheduled to settle on March 12, 2021. The notes will have a 1.250% interest rate, maturing on March 15, 2026, and an initial exchange price of approximately $21.21 per share, reflecting a 32.5% premium. Net proceeds are estimated at $120.6 million, intended for refinancing existing preferred stock and general corporate purposes. The company has also entered into capped call transactions to mitigate potential stock dilution from note exchanges.
Avid Bioservices, Inc. (NASDAQ:CDMO, CDMOP) announced plans to sell $125 million in exchangeable senior notes due 2026 through its subsidiary, Avid SPV, LLC. The notes will be privately placed with qualified institutional buyers and will come with an option for an additional $18.75 million. Proceeds are earmarked for redeeming Series E Convertible Preferred Stock and general corporate purposes, including potential acquisitions. The notes will allow holders to exchange them for shares during specific periods. The offering is subject to market conditions.
FAQ
What core services does Avid Bioservices provide?
How does Avid Bioservices serve the biotech and pharmaceutical industries?
What distinguishes Avid Bioservices in the competitive CDMO market?
How does Avid ensure quality and compliance in its manufacturing processes?
What is the significance of process development in Avid Bioservices' operations?
How does Avid Bioservices support its clients throughout the product lifecycle?
Who are the typical customers of Avid Bioservices?
How does Avid Bioservices maintain its industry expertise?
